愛柯迪(600933.SH):擬與南京永升等設南京迪升動力科技有限公司
格隆匯5月7日丨愛柯迪(600933.SH)公佈,根據公司整體戰略佈局的規劃以及業務發展的需要,公司擬與南京永升新能源技術有限公司、江蘇舜天盛泰工貿有限公司,自然人陳立秋、馬貴耀、陳悦蘋,南京眾行創業諮詢合夥企業(有限合夥)共同出資設立南京迪升動力科技有限公司。
南京迪升註冊資本為人民幣6250萬元,公司擬以自有資金認繳出資人民幣2500萬元,佔註冊資本的40%。
通過此次合作,公司將與各方投資者建立強強聯合、優勢互補的戰略合作關系。此次合作有利於公司業務的發展壯大,將有利於拓展公司產品結構,豐富公司產品類型,拓展公司銷售渠道,提升公司的經營業績,符合公司戰略發展方向。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.